Compare EXPO & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | IDYA |
|---|---|---|
| Founded | 1967 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 1990 | 2019 |
| Metric | EXPO | IDYA |
|---|---|---|
| Price | $73.85 | $34.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $81.00 | $49.18 |
| AVG Volume (30 Days) | 435.7K | ★ 904.3K |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $531,142,000.00 | $214,834,000.00 |
| Revenue This Year | $5.35 | $2,662.86 |
| Revenue Next Year | $7.90 | N/A |
| P/E Ratio | $34.56 | ★ N/A |
| Revenue Growth | 4.43 | ★ 5377.66 |
| 52 Week Low | $63.81 | $13.45 |
| 52 Week High | $97.57 | $37.08 |
| Indicator | EXPO | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 53.89 |
| Support Level | $68.50 | $34.04 |
| Resistance Level | $75.01 | $35.28 |
| Average True Range (ATR) | 1.86 | 1.14 |
| MACD | -0.23 | -0.14 |
| Stochastic Oscillator | 64.64 | 63.05 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.